OcuTer­ra’s di­a­bet­ic retinopa­thy drug fails PhII; Bet­ter Ther­a­peu­tics to shut down

Plus, news about Im­muneer­ing, Adi­tum Bio, Uni­cy­cive and X-Ther­ma:

OcuTer­ra Ther­a­peu­tics’ di­a­bet­ic retinopa­thy drug fails PhII: The com­pa­ny’s RGD in­te­grin in­hibitor

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER